Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Factors impacting response to ICIs in mUC

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, discusses the impact of primary tumor location, histology, and host factors on objective response to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC). The findings from this retrospective analysis, explained by Dr Gupta, showed no correlation between host and tumor factors, and treatment response or duration of response in patients. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.